

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-K**

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended December 31 , 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-01136

**BRISTOL-MYERS SQUIBB COMPANY**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

22-0790350  
( I.R.S Employer  
Identification No.)

Route 206 & Province Line Road , Princeton , New Jersey 08543

(Address of principal executive offices)

( 609 ) 252-4621

( Registrant's telephone number, including area code )

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of each class</u>      | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
|---------------------------------|--------------------------|--------------------------------------------------|
| Common Stock, \$0.10 Par Value  | BMY                      | New York Stock Exchange                          |
| 1.000% Notes due 2025           | BMY25                    | New York Stock Exchange                          |
| 1.750% Notes due 2035           | BMY35                    | New York Stock Exchange                          |
| Celgene Contingent Value Rights | CELG RT                  | New York Stock Exchange                          |

Securities registered pursuant to Section 12(g) of the Act:

Title of each class  
\$2 Convertible Preferred Stock, \$1 Par Value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒  
No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐  
No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of " large accelerated filer ," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

JHU 2246

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the 2,087,551,048 shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of the registrant's most recently completed second fiscal quarter was approximately \$ 133,498,889,520 . Bristol-Myers Squibb Company has no non-voting common equity. At February 6, 2024, there were 2,022,193,411 shares of common stock outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE:** Portions of the definitive proxy statement for the registrant's Annual Meeting of Shareholders to be filed within 120 days after the conclusion of the registrant's fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.

---

---

**BRISTOL-MYERS SQUIBB COMPANY**  
**INDEX TO FORM 10-K**  
December 31, 2023

|                                     |                                                                                                       |            |
|-------------------------------------|-------------------------------------------------------------------------------------------------------|------------|
| <u>PART I</u>                       |                                                                                                       |            |
| Item 1.                             | <u>Business</u>                                                                                       | <u>1</u>   |
|                                     | <u>Acquisitions, Divestitures and Licensing Arrangements</u>                                          | <u>2</u>   |
|                                     | <u>Products, Intellectual Property and Product Exclusivity</u>                                        | <u>2</u>   |
|                                     | <u>Research and Development</u>                                                                       | <u>7</u>   |
|                                     | <u>Alliances</u>                                                                                      | <u>13</u>  |
|                                     | <u>Marketing, Distribution and Customers</u>                                                          | <u>13</u>  |
|                                     | <u>Competition</u>                                                                                    | <u>14</u>  |
|                                     | <u>Pricing, Price Constraints and Market Access</u>                                                   | <u>15</u>  |
|                                     | <u>Government Regulation</u>                                                                          | <u>16</u>  |
|                                     | <u>Sources and Availability of Raw Materials</u>                                                      | <u>18</u>  |
|                                     | <u>Manufacturing and Quality Assurance</u>                                                            | <u>19</u>  |
|                                     | <u>Environmental Regulation</u>                                                                       | <u>20</u>  |
|                                     | <u>Human Capital Management and Resources</u>                                                         | <u>20</u>  |
|                                     | <u>Foreign Operations</u>                                                                             | <u>22</u>  |
|                                     | <u>Bristol Myers Squibb Website</u>                                                                   | <u>22</u>  |
| Item 1A.                            | <u>Risk Factors</u>                                                                                   | <u>23</u>  |
| Item 1B.                            | <u>Unresolved Staff Comments</u>                                                                      | <u>33</u>  |
| Item 1C.                            | <u>Cybersecurity</u>                                                                                  | <u>33</u>  |
| Item 2.                             | <u>Properties</u>                                                                                     | <u>34</u>  |
| Item 3.                             | <u>Legal Proceedings</u>                                                                              | <u>34</u>  |
| Item 4.                             | <u>Mine Safety Disclosures</u>                                                                        | <u>34</u>  |
| <u>PART IA</u>                      | <u>Information about our Executive Officers</u>                                                       | <u>35</u>  |
| <u>PART II</u>                      |                                                                                                       |            |
|                                     | <u>Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of</u> |            |
| Item 5.                             | <u>Equity Securities</u>                                                                              | <u>36</u>  |
| Item 6.                             | <u>[Reserved]</u>                                                                                     | <u>37</u>  |
| Item 7.                             | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>          | <u>38</u>  |
| Item 7A.                            | <u>Quantitative and Qualitative Disclosures About Market Risk</u>                                     | <u>69</u>  |
| Item 8.                             | <u>Financial Statements and Supplementary Data</u>                                                    | <u>71</u>  |
|                                     | <u>Consolidated Statements of Earnings and Comprehensive Income</u>                                   | <u>71</u>  |
|                                     | <u>Consolidated Balance Sheets</u>                                                                    | <u>72</u>  |
|                                     | <u>Consolidated Statements of Cash Flows</u>                                                          | <u>73</u>  |
|                                     | <u>Notes to the Financial Statements</u>                                                              | <u>74</u>  |
| Item 9.                             | <u>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>           | <u>123</u> |
| Item 9A.                            | <u>Controls and Procedures</u>                                                                        | <u>123</u> |
| Item 9B.                            | <u>Other Information</u>                                                                              | <u>123</u> |
| Item 9C.                            | <u>Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</u>                            | <u>123</u> |
| <u>PART III</u>                     |                                                                                                       |            |
| Item 10.                            | <u>Directors, Executive Officers and Corporate Governance</u>                                         | <u>125</u> |
| Item 11.                            | <u>Executive Compensation</u>                                                                         | <u>125</u> |
|                                     | <u>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder</u>         |            |
| Item 12.                            | <u>Matters</u>                                                                                        | <u>125</u> |
| Item 13.                            | <u>Certain Relationships and Related Transactions</u>                                                 | <u>125</u> |
| Item 14.                            | <u>Principal Accountant Fees and Services</u>                                                         | <u>125</u> |
| <u>PART IV</u>                      |                                                                                                       |            |
| Item 15.                            | <u>Exhibits and Financial Statement Schedule</u>                                                      | <u>126</u> |
| Item 16.                            | <u>Form 10-K Summary</u>                                                                              | <u>126</u> |
| <u>SIGNATURES</u>                   |                                                                                                       | <u>127</u> |
| <u>SUMMARY OF ABBREVIATED TERMS</u> |                                                                                                       | <u>129</u> |
| <u>EXHIBIT INDEX</u>                |                                                                                                       | <u>130</u> |

\* Indicates brand names of products which are trademarks not owned by BMS. Specific trademark ownership information is included in the Exhibit Index at the end of this 2023 Form 10-K.

---

## Product Revenues

| Dollars in millions<br>In-Line Products | Year Ended December 31, |           |          |
|-----------------------------------------|-------------------------|-----------|----------|
|                                         | 2023                    | 2022      | % Change |
| <i>Eliquis</i>                          | 12,206                  | \$ 11,789 | 4 %      |
| U.S.                                    | 8,592                   | 7,786     | 10 %     |
| Non-U.S.                                | 3,614                   | 4,003     | (10)%    |
| <i>Opdivo</i>                           | 9,009                   | 8,249     | 9 %      |
| U.S.                                    | 5,283                   | 4,812     | 10 %     |
| Non-U.S.                                | 3,726                   | 3,437     | 8 %      |
| <i>Orencia</i>                          | 3,601                   | 3,464     | 4 %      |
| U.S.                                    | 2,754                   | 2,638     | 4 %      |
| Non-U.S.                                | 847                     | 826       | 3 %      |
| <i>Pomalyst/Imnovid</i>                 | 3,441                   | 3,497     | (2)%     |
| U.S.                                    | 2,357                   | 2,438     | (3)%     |
| Non-U.S.                                | 1,084                   | 1,059     | 2 %      |
| <i>Yervoy</i>                           | 2,238                   | 2,131     | 5 %      |
| U.S.                                    | 1,388                   | 1,304     | 6 %      |
| Non-U.S.                                | 850                     | 827       | 3 %      |
| <i>Sprycel</i>                          | 1,930                   | 2,165     | (11)%    |
| U.S.                                    | 1,446                   | 1,497     | (3)%     |
| Non-U.S.                                | 484                     | 668       | (28)%    |
| Mature and other products               | 1,895                   | 2,045     | (7)%     |
| U.S.                                    | 772                     | 750       | 3 %      |
| Non-U.S.                                | 1,123                   | 1,295     | (13)%    |
| Total In-Line Products                  | 34,320                  | 33,340    | 3 %      |
| U.S.                                    | 22,592                  | 21,225    | 6 %      |
| Non-U.S.                                | 11,728                  | 12,115    | (3)%     |